Back

Factor XI inhibitors or direct oral anticoagulants in atrial fibrillation: an updated meta-analysis

1 September 2025 (14:50 - 15:00)
Organised by: Logo
Congress Presentation Part of: Oral anticoagulation in atrial fibrillation: new insights Oral Anticoagulation ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Mattia Galli

Sapienza University of Rome, Rome (Italy)

4 More presentations in this session

Presentation thumbnail
Prior anticoagulation experience, bleeding risk, and safety of factor XI inhibition in atrial fibrillation: an analysis of AZALEA-TIMI 71
Doctor S. Patel (Boston, US)
Abstract Slides
Presentation thumbnail
Validation of the DOAC Score among patients on vitamin K antagonists
Doctor R. Aggarwal (Boston, US)
Abstract Slides
Presentation thumbnail
Renal function and factor XI inhibition in atrial fibrillation: a pre-specified analysis of AZALEA-TIMI 71
Doctor S. Patel (Boston, US)
Abstract Slides
Presentation thumbnail
Renal function and long-term outcomes in edoxaban-treated patients: A subanalysis from ETNA-AF Europe 4 years follow up
Professor R. De Caterina (Pisa, IT)
Abstract Slides

Access the full session

Session thumbnail
Oral anticoagulation in atrial fibrillation: new insights
Video

The Event

Event poster

ESC Congress 2025

1 September 2025 14:50 CET
You may be interested in
thumbnail
Congress Session
Stroke prevention in clinical and subclinical atrial fibrillation
thumbnail
Congress Presentation
State-of-the-art lecture on stroke and bleeding risk in atrial fibrillation: walking the tight rope
thumbnail
Congress Session
Oral anticoagulation in subclinical atrial fibrillation

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources